• Cowen & Co. maintains a "Buy" rating for Amgen Inc. (NASDAQ:AMGN), raising the price target from $389 to $420.
• Amgen's Q4 performance in 2025 exceeded expectations, with key products like Repatha and Uplizna expected to drive future growth.
• Despite regulatory uncertainties and pipeline attrition, Amgen's long-term prospects remain strong, supported by positive data from Repatha and progress with MariTide.

Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies. On February 4, 2026, Cowen & Co. maintained a "Buy" rating for Amgen, with the stock trading at $338.59. TD Cowen also raised Amgen's price target from $389 to $420, as highlighted by TheFly, indicating confidence in the company's future performance.

Amgen's strong fourth-quarter performance in 2025 exceeded expectations for both revenue and earnings per share. This robust performance supports the positive outlook from analysts. Despite challenges from the loss of exclusivity on some products, Amgen's guidance for growth in 2026 remains optimistic. Key products like Repatha and Uplizna are expected to offset losses from Prolia and Xgeva.

However, Amgen faces regulatory uncertainty with Tavneos, which could impact its growth. Additionally, pipeline attrition, including setbacks with rocatinlimab and bemarituzumab, presents challenges. Despite these hurdles, positive data from Repatha and progress with MariTide provide a strong foundation for Amgen's long-term prospects.

Amgen's stock price is currently $338.59, reflecting a 1.80% decrease or $6.20 drop. The stock has fluctuated between $338.59 and $349.50 today. Over the past year, it reached a high of $353.25 and a low of $261.43. Amgen's market capitalization is approximately $182.32 billion, with a trading volume of 4,027,278 shares.